RE:RE:IPA - revenue streams, services,... Hi wallpaper2,
I was trying to express that IPA partners immediately with large pharma (and small). They are a very different sort of company. They might announce a new partnership on another product tomorrow. They are not like a traditional biopharma startup which might have one or two products that they run through trials for 10 years with the hope of commercialization or a partnership at the end of th rainbow. (I have bought and run with at least one such company for the past 20 years without a partnership. It's not very fun, but it is interesting.)
Go through their investor presentation of May 2021. You will find many different pages which I hope will illustrate my point. It is not directly conflicting with your point. The IR representative may have been responding to a question that you posed about where they are at with trials with one or more of their partners. However, I think that the unique and powerful aspect of IPA is that they collaborate and develop other people's ideas, on a contract basis, within a partnership from day one. They get paid for that service.
Here's an example of one page from their Investor presentation:
Customized to optimize antibody diversity & support clinical success
> Unparalleled, integrated capabilities and expertise
> Enables selection of ideal, customized campaign
> Extensive options for customizable deliverables
> Eliminate need for additional vendors
> Our scientific excellence and innovative technologies are a proven combo for success
> Thousands of programs completed
> Over 500 clients worldwide
Our single-source, open-access biologics technology platform offers end-to-end solutions, empowering partners to discover and develop
biologics from concept to clinical lead.
Clients include 70% of top 20 pharma